Pfizer launches new oral medication Rimegepant in India for rapid migraine relief and acute treatment

Global pharmaceutical company Pfizer has announced the launch of Rimegepant Orally Disintegrating Tablet (ODT) in India for the acute treatment of migraine in adults who have previously responded inadequately to triptan.

“The new drug provides rapid and sustained pain relief lasting up to 48 hours after treatment, while eliminating the risk of headaches due to drug overuse. It also allows early return to function and long-lasting relief of the most bothersome symptoms. Rimegepant will be available in the form of a 75 mg orally disintegrating tablet (ODT), designed for easy administration without the need for water,” said a statement issued by the company.

It added that by targeting one of the key elements of migraine pathophysiology – calcitonin gene-related peptide (CGRP) – this drug provides fast and effective relief.

Meenakshi Nevatia, MD, Pfizer Ltd., India, said: “We believe this treatment will help people with migraine manage pain more effectively and regain productive days faster than currently available options.”